Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells

Bioanalysis

Volumn 7, Issue 5, 2015, Pages 519-529

  Pluim, Dick ^a   Jacobs, Bart A ^a   Deenen, Maarten J ^a   Ruijter, Anneloes E ^a   Van Geel, Robin M ^a   Burylo, Artur M ^a   Meulendijks, Didier ^a   Beijnen, Jos H ^a,b   Schellens, Jan H ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; EPIRUBICIN; HEMOGLOBIN; OXALIPLATIN; THYMINE;

ARTICLE; CELL LYSATE; CLINICAL ARTICLE; CONTAMINATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; ENZYME ACTIVITY; ENZYME ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPH; LIQUID SCINTILLATION COUNTING; MEASUREMENT ACCURACY; MUCOSA INFLAMMATION; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETER; SPECTROPHOTOMETRY; STORAGE TEMPERATURE; THERMOSTABILITY; VALIDATION STUDY; METABOLISM; MONONUCLEAR CELL; PROCEDURES;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROURACIL DEHYDROGENASE (NADP); HUMANS; LEUKOCYTES, MONONUCLEAR;

EID: 84926334621     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.304     Document Type: Article

References (28)

1. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur. J. Cancer 43(6), 1011-1016 (2007).
2. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer 79(3-4), 627-630 (1999).
3. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv. Enzyme Regul. 41, 151-157 (2001).
4. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 40(7), 939-950 (2004).
5. Rosmarin D, Palles C, Church D et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J. Clin. Oncol. 32(10), 1031-1039 (2014).
6. Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin. Colorectal. Cancer 9(4), 224-228 (2010).
7. Zhang X, Li L, Fourie J, Davie JR, Guarcello V, Diasio RB. The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochim. Biophys. Acta 1759(5), 247-256 (2006).
8. Etienne MC, Lagrange JL, Dassonville O et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12(11), 2248-2253 (1994).
9. Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin. Colorectal. Cancer 6(4), 288-296 (2006).
10. Ciccolini J, Mercier C, Evrard A et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther. Drug Monit. 28(5), 678-685 (2006).
11. Ostapowicz A, Dolegowska B. Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil. Przeglad Lekarski 69(9), 694-697 (2012).
12. van Staveren MC, Guchelaar HJ, van Kuilenburg AB, Gelderblom H, Maring JG. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J. 13(5), 389-395 (2013).
13. van Kuilenburg AB, van Lenthe H, Zoetekouw L, Kulik W. HPLC-electrospray tandem mass spectrometry for rapid determination of dihydropyrimidine dehydrogenase activity. Clin. Chem. 53(3), 528-530 (2007).
14. Van Kuilenburg AB, Van Lenthe H, Van Gennip AH. Identification and tissue-specific expression of a NADHdependent activity of dihydropyrimidine dehydrogenase in man. Anticancer Res. 16(1), 389-394 (1996).
15. van Kuilenburg AB, van Lenthe H, Tromp A, Veltman PC, van Gennip AH. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin. Chem. 46(1), 9-17 (2000).
16. Jansen RS, Rosing H, Schellens JH, Beijnen JH. Protein versus DNA as a marker for peripheral blood mononuclear cell counting. Anal. Bioanal. Chem. 395(3), 863-867 (2009).
17. Pluim D, Jacobs BA, Krahenbuhl MD, Ruijter AE, Beijnen JH, Schellens JH. Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination. Anal. Bioanal. Chem. 405(7), 2391-2395 (2013).
18. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand. J. Clin. Lab. Invest. Suppl. 97, 77-89 (1968).
19. Boyum A. Isolation of leucocytes from human blood. A twophase system for removal of red cells with methylcellulose as erythrocyte-aggregating agent. Scand. J. Clin. Lab. Invest. Suppl. 97, 9-29 (1968).
20. Matt P, Zwieten-Boot B, Calvo Rojas G et al. The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP). Oncologist 16(10), 1451-1457 (2011).
21. Deenen MJ, Tol J, Burylo AM et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res. 17(10), 3455-3468 (2011).
22. ICRP Publication 61. Annual Limits on Intake of Radionuclides by Workers Based on the 1990 Recommendations, Elsevier (1991).
23. Scopes RK. Enzyme Activity and Assays. John Wiley & Sons Ltd, West Sussex, United Kingdom (2002).
24. Chandran S, Singh RS. Comparison of various international guidelines for analytical method validation. Die Pharmazie 62(1), 4-14 (2007).
25. Deenen MJ, Cats A, Sechterberger MK et al. Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. J. Clin. Oncol. 29, abstract 3606 (2011).
26. Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 74(9), 2545-2554 (2014).
27. van Kuilenburg AB, Meijer J, Mul AN et al. Intragenic deletions and a deep intronic mutation affecting premRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum. Genet. 128(5), 529-538 (2010).
28. Wood PA, Du-Quiton J, You S, Hrushesky WJ. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol. Cancer Ther. 5(8), 2023-2033 (2006).